APF Research Fund

admin@apf-2018 |

The Australian Pituitary Foundation is proud of its history in supporting patients and families living with pituitary conditions through the provision of information, seminars and community support. It has kept a strong eye towards research and through its community connections been associated with several large-scale research projects in the past.

The Board of the APF ratified a decision to establish the APF Research Fund earlier in the year with the aim of a launch by March 2020. This will be an annual fund with the aim to support researchers specifically investigating pituitary conditions to improve the clinical outcomes and quality of life of our community. Unfortunately due to the current personal and economic circumstances around the Covid-19 situation it was elected to postpone the formal launch until individual confidence is re-established.

The reality however is this – pituitary conditions are still being diagnosed today. Every week twenty-five to thirty new pituitary tumours are diagnosed in Australia encompassing around 20-25 non-functioning adenomas, 5-8 acromegalics and 1-2 Cushing’s disease. Non-tumourous pituitary conditions also continue to be diagnosed, the incidence of which are more difficult to estimate. Patients continue to need treatment for these conditions and it is for these patients that we are proceeding with a soft launch of the APF Research Fund.

In these difficult situations I would ask for you to consider those attempting to cope with their individual medical conditions, as well as navigating the Covid-19 situation. Every little cent will count towards improving the lives of the pituitary patient and their families. You can donate now using this link https://pituitary.asn.au/donate-now/

For 2020, we are pleased to announce the recipient of the APF Research Fund to be A/Professor Ann McCormack of the Garvan Institute and St Vincent’s Hospital (Sydney). A/Professor McCormack is Australia’s leading researcher in pituitary conditions, combining clinical research with ground-breaking genetic research. Her translational work has impacted many pituitary patients with the establishment of clinical trials enabling patients to access treatments that are otherwise prohibitably expensive and out of reach. The establishment of the pituitary tumour BioBank through the Garvan Institute is paramount to this and the continued funding of this imperative to allow this work to continue. A specific example of the impact of her work can be seen here https://www.stvincentsclinic.com.au/newsroom/news/rare-disease-day-uncovering-novel-treatments-for-pituitary-tumour

Thank you for digging deep to support this cause especially during these difficult times. We thank you. A/Professor McCormack thanks you. But most importantly the Pituitary Patient and their families thank you.

Yi Yuen